Hydrogel nanocarrier delivery system for targeting activated CD44 molecules, its preparation method and use

Abstract

A hydrogel nanocarrier delivery system for targeting activated CD44 molecules and a preparation method thereof, the surface of the nanocarrier is partially modified by a targeting ligand, and the targeting ligand is capable of interacting with activated CD44 A ligand to which a molecule specifically binds. The application of the hydrogel nano-carrier delivery system in the preparation of medicines for diagnosis, prevention and treatment of vulnerable plaques or diseases related to vulnerable plaques.

Description

[0001] Cross References to Related Applications [0002] This application claims the priority of the Chinese invention patent application No. CN201810060265.9 submitted on January 22, 2018, which is incorporated herein by reference. technical field [0003] The invention belongs to the technical field of targeted drug delivery, and in particular relates to a nano-carrier for targeting and activating CD44 molecules, especially for targeting vulnerable plaques, especially a hydrogel nano-delivery system. The present invention also relates to the preparation method and use of the nano-carrier, especially the hydrogel nano-delivery system, especially the use in the diagnosis, prevention and treatment of vulnerable plaque or diseases related to vulnerable plaque. Background technique [0004] At present, acute cardiovascular events, mainly acute myocardial infarction and sudden cardiac death, have become the number one killer of human health. According to statistics, about 20 m...

AI Technical Summary

Problems solved by technology

Therefore, the following problems will be encountered in the research and development of targeted drug delivery systems targeting CD44: if the affinity between CD44 and HA on the surface of target cells is not enough to provide significant specificity, then such targeted drug delivery systems will be difficult to obtain. There will be no specific targeting properties

[0014] So far, there is no report on the expression status of CD44 on the surface of macrophages, monocytes, endothelial cells, lymphocytes and smooth muscle cells mainly present in vulnerable plaques and its affinity for HA, nor does it exist. Any targeted drug delivery capable of stable and sustained release of drugs designed for the diagnosis or treatment of vulnerable plaques or diseases associated with vulnerable plaques using the interaction of HA and CD44 and the specific microenvironment of vulnerable plaques system prior art

Images